Amgen forecast darkens as FDA review looms

The FDA couldn't have scheduled today's meeting on the risks posed by Amgen's anemia drugs at a worse time. With the market opening to a new raft of chilly economic reports, analysts covering Amgen were in a particularly dour mood about Amgen's chances. Christopher Raymond at Robert W. Baird predicted more restrictions on the use of its multibillion-dollar drugs, which would further eat into the biotech company's revenue. And FBR Capital's Jim Reddoch wouldn't even rule out a vote to remove Aranesp from the market--a worst-case scenario that would inflict major damage at a company that has been working to build up a pipeline of new therapies needed to rescue its bottom line.

Amgen officials, though, will fight this battle over the $6 billion market to the bitter finish.

"ESAs provide an unequivocal treatment benefit for cancer patients undergoing chemotherapy by reducing the need for blood transfusions," said Roger M. Perlmutter, Amgen's executive vice president of research and development.

- see Amgen's release
- read the story from CNN
and check out the Dow Jones report

Related Articles:
Epogen/Aranesp--Top 10 Warnings and Recalls. Report
FDA's worst-case anemia scenario. Report
Do anemia warnings signal new limits? Report
Study: Anemia meds hike death risk 10%. Report
FDA: More risks from anemia drugs. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.